Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 18:10:1008.
doi: 10.3389/fgene.2019.01008. eCollection 2019.

Genomic Profiling of Driver Gene Mutations in Chinese Patients With Non-Small Cell Lung Cancer

Hongxue Meng  1 , Xuejie Guo  2 , Dawei Sun  3 , Yuebin Liang  2 , Jidong Lang  2 , Yingmin Han  2 , Qingqing Lu  2 , Yanxiang Zhang  2 , Yanxin An  2 , Geng Tian  2 , Dawei Yuan  2 , Shidong Xu  3 , Jingshu Geng  1
Affiliations

Genomic Profiling of Driver Gene Mutations in Chinese Patients With Non-Small Cell Lung Cancer

Hongxue Meng et al. Front Genet. .

Abstract

Worldwide, especially in China, lung cancer accounts to a major cause of mortality related to cancer. Treatment decisions mainly depend on oncogenic driver mutations, which offer novel therapeutic targets for anticancer therapy. However, studies of genomic profiling of driver gene mutations in mainland China are rare. Hence, this is an extensive study of these mutations in Non-small-cell lung cancer (NSCLC) Chinese patients. Comparison of driver gene mutations of lung adenocarcinoma with other races showed that the mutational frequencies were similar within the different East Asian populations, while there were differences between East Asian and non-Asian populations. Further, four promising candidates for druggable mutations of epidermal growth factor receptor (EGFR) were revealed that open up avenues to develop and design personal therapeutic approaches for patients harboring mutations. These results will help to develop personalized therapy targeting NSCLC.

Keywords: EGFR; driver mutations; epidemiology; lung cancer; personalized medicine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A), The mutation sites and frequency of EGFR and (B) KRAS in 3,423 patients with lung adenocarcinoma.
Figure 2
Figure 2
Four-set venn-diagram of single and multiple mutation panoramagram for lung adenocarcinoma tissue samples.
Figure 3
Figure 3
Three-dimensionional (3D) models of (A) the EGFRQ. kinase domain-Gefitinib complex structure (PDB: 2ITY), (B) the EGFR kinase domain-Afatinib complex structure (PDB: 4G5J). Gefitinib and Afatinib are shown as sticks. Residues at the mutation site of the EGFR kinase domains (V742, I789, N842 and S811) are shown with arrows.
See this image and copyright information in PMC

References

    1. Asahina H., Yamazaki K., Kinoshita I., Yokouchi H., Dosaka-Akita H., Nishimura M. (2007). Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. Lung Cancer 54, 419–422. 10.1016/j.lungcan.2006.09.005 - DOI - PubMed
    1. Azzoli C. G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. (2010). [American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer]. Chin. J. Lung Cancer 13, 171–189. 10.3779/j.issn.1009-3419.2010.03.15 - DOI - PMC - PubMed
    1. Campbell J. D., Lathan C., Sholl L., Ducar M., Vega M., Sunkavalli A., et al. (2017). Comparison of prevalence and types of mutations in lung cancers among black and white populations. JAMA Oncol. 3, 801. 10.1001/jamaoncol.2016.6108 - DOI - PMC - PubMed
    1. D’Addario G., Felip E.E.G.W. Group (2009). Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20 Suppl 4, 68–70. 10.1093/annonc/mdp132 - DOI - PubMed
    1. D’Angelo S. P., Pietanza M. C., Johnson M. L., Riely G. J., Miller V. A., Sima C. S., et al. (2011). Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J. Clin. Oncol. 29, 2066–2070. 10.1200/JCO.2010.32.6181 - DOI - PMC - PubMed